Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection.
Joshua DorazioAbby L ChiappelliRyan K ShieldsY Vivian TsaiPeyton SkinkerMichael J NaboznyGraciela BauzaRaquel ForsytheMatthew R RosengartScott R GunnRachel MariniLloyd ClarkeBonnie FalcioneJustin LudwigErin K McCrearyPublished in: Open forum infectious diseases (2023)
In this small, retrospective, single-center, quasi-experimental study, there was no difference in 30-day mortality in patients receiving treatment with clindamycin plus vancomycin versus linezolid in combination with standard gram-negative and anaerobic therapy and surgical debridement for the treatment of NSTIs. A composite outcome of death, AKI, or CDI within 30 days was more common in the clindamycin plus vancomycin group.